Drug Ther Bull. 2015 Sep;53(9):105-8. doi: 10.1136/dtb.2015.9.0352.
▼ Apremilast (Otezla - Celgene Europe Ltd.) is a novel orally administered immunomodulatory medicine licensed for the treatment of plaque psoriasis and psoriatic arthritis. The company suggests that it has demonstrated proven and durable efficacy in both conditions and has a favourable safety profile with no requirement for drug-specific pre-screening or ongoing laboratory monitoring. Here we review the evidence on the safety and efficacy of apremilast in the management of psoriasis and psoriatic arthritis.
▼ 阿普斯特（奥贝胆酸 - 新基欧洲有限公司）是一种新型口服免疫调节药物，已获许可用于治疗斑块状银屑病和银屑病关节炎。该公司表示，它在这两种病症中均已证明具有可靠且持久的疗效，并且安全性良好，无需进行特定药物的预筛查或持续的实验室监测。在此，我们回顾关于阿普斯特治疗银屑病和银屑病关节炎的安全性和疗效的证据。
